NZ748592A - Treatment for parkinson’s disease - Google Patents

Treatment for parkinson’s disease

Info

Publication number
NZ748592A
NZ748592A NZ748592A NZ74859217A NZ748592A NZ 748592 A NZ748592 A NZ 748592A NZ 748592 A NZ748592 A NZ 748592A NZ 74859217 A NZ74859217 A NZ 74859217A NZ 748592 A NZ748592 A NZ 748592A
Authority
NZ
New Zealand
Prior art keywords
3haloalkyl
hydrogen
disease
halogen
parkinson
Prior art date
Application number
NZ748592A
Other languages
English (en)
Inventor
Nitin Krishnaji Damle
Sanjay Nandlalji Mandhane
Manoj Atmaramji Upadhya
Sameer Vishwanath Mehetre
Gajanan Uttamrao Chidrewar
Prabal Sengupta
Trinadha Rao Chitturi
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of NZ748592A publication Critical patent/NZ748592A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ748592A 2016-06-02 2017-06-02 Treatment for parkinson’s disease NZ748592A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201621019087 2016-06-02
IN201621019185 2016-06-02
PCT/IN2017/050224 WO2017208267A1 (en) 2016-06-02 2017-06-02 Treatment for parkinson's disease

Publications (1)

Publication Number Publication Date
NZ748592A true NZ748592A (en) 2025-11-28

Family

ID=59388123

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ748592A NZ748592A (en) 2016-06-02 2017-06-02 Treatment for parkinson’s disease

Country Status (27)

Country Link
US (4) US10849887B2 (show.php)
EP (2) EP3463351B1 (show.php)
JP (1) JP6974357B2 (show.php)
KR (1) KR102508288B1 (show.php)
CN (1) CN109475539B (show.php)
AU (1) AU2017273415B2 (show.php)
CA (1) CA3024976A1 (show.php)
CL (1) CL2018003431A1 (show.php)
CY (1) CY1125285T1 (show.php)
DK (1) DK3463351T3 (show.php)
ES (1) ES2914782T3 (show.php)
HR (1) HRP20220683T1 (show.php)
HU (1) HUE059387T2 (show.php)
IL (1) IL263188B (show.php)
LT (1) LT3463351T (show.php)
MX (1) MX385276B (show.php)
MY (1) MY193754A (show.php)
NZ (1) NZ748592A (show.php)
PH (1) PH12018502457B1 (show.php)
PL (1) PL3463351T3 (show.php)
PT (1) PT3463351T (show.php)
RS (1) RS63243B1 (show.php)
SG (1) SG11201810294QA (show.php)
SI (1) SI3463351T1 (show.php)
SM (1) SMT202200228T1 (show.php)
UA (1) UA123018C2 (show.php)
WO (1) WO2017208267A1 (show.php)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2943113T3 (es) 2012-05-02 2023-06-09 Univ Georgetown Tratamiento de la esclerosis lateral amiotrófica con inhibidores de las tirosina cinasas
HRP20220683T1 (hr) 2016-06-02 2022-07-08 Sun Pharma Advanced Research Company Limited Liječenje parkinsonove bolesti
CN110606840A (zh) 2018-06-15 2019-12-24 日产化学株式会社 5-炔基吡啶化合物的制造方法
JP7629200B2 (ja) 2018-11-20 2025-02-13 ジョージタウン ユニバーシティ 神経変性、筋変性及びリソソーム蓄積障害を治療するための組成物及び方法
EA202193211A1 (ru) * 2019-06-11 2022-03-30 Сан Фарма Эдванст Рисерч Компани Лтд. Лечение синуклеопатий
WO2021030783A1 (en) * 2019-08-15 2021-02-18 Duke University Compositions and methods for the treatment cancer and cns disorders
MX2023001358A (es) 2020-07-31 2023-02-27 Sun Pharma Advanced Res Co Ltd N´-(2-cloro-6-metilbenzoil)-4-metil-3-[2-(3-quinolil) etinil]-benzohidrazida para el tratamiento de la enfermedad de alzheimer.
JP2025517624A (ja) 2022-05-02 2025-06-10 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド パーキンソン病の進行を低減するためのボドバチニブ
KR20250040552A (ko) 2023-09-14 2025-03-24 주식회사 엑소스템텍 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013018212B1 (pt) * 2011-01-21 2021-12-14 Sun Pharma Advanced Research Company Ltd Inibidores de tirosino quinase contendo diarilacettleno hidrazida
ES2943113T3 (es) 2012-05-02 2023-06-09 Univ Georgetown Tratamiento de la esclerosis lateral amiotrófica con inhibidores de las tirosina cinasas
JP6689887B2 (ja) * 2015-05-18 2020-04-28 スン プハルマ アドバンセド リサーチ カンパニー リミテド 新規アミドヘテロアリールアロイルヒドラジドエチン
HRP20220683T1 (hr) * 2016-06-02 2022-07-08 Sun Pharma Advanced Research Company Limited Liječenje parkinsonove bolesti

Also Published As

Publication number Publication date
LT3463351T (lt) 2022-06-10
PT3463351T (pt) 2022-06-02
CA3024976A1 (en) 2017-12-07
AU2017273415A1 (en) 2018-12-06
US11813252B2 (en) 2023-11-14
HRP20220683T1 (hr) 2022-07-08
MX385276B (es) 2025-03-18
SG11201810294QA (en) 2018-12-28
PL3463351T3 (pl) 2022-06-20
EP3463351B1 (en) 2022-04-27
CL2018003431A1 (es) 2019-05-10
PH12018502457B1 (en) 2022-01-12
EP3463351A1 (en) 2019-04-10
US11583522B2 (en) 2023-02-21
CN109475539B (zh) 2021-12-28
MY193754A (en) 2022-10-27
US20210015805A1 (en) 2021-01-21
WO2017208267A1 (en) 2017-12-07
IL263188A (en) 2018-12-31
US20240066014A1 (en) 2024-02-29
US20190275017A1 (en) 2019-09-12
CN109475539A (zh) 2019-03-15
IL263188B (en) 2021-08-31
KR20190015257A (ko) 2019-02-13
EP4085912A1 (en) 2022-11-09
AU2017273415B2 (en) 2023-01-19
DK3463351T3 (da) 2022-06-07
ES2914782T3 (es) 2022-06-16
CY1125285T1 (el) 2025-03-28
US10849887B2 (en) 2020-12-01
SMT202200228T1 (it) 2022-07-21
MX2018014944A (es) 2019-03-07
KR102508288B1 (ko) 2023-03-09
PH12018502457A1 (en) 2019-10-21
JP2019520344A (ja) 2019-07-18
US20220273632A1 (en) 2022-09-01
SI3463351T1 (sl) 2022-07-29
RS63243B1 (sr) 2022-06-30
BR112018074439A2 (pt) 2019-03-06
UA123018C2 (uk) 2021-02-03
HUE059387T2 (hu) 2022-11-28
JP6974357B2 (ja) 2021-12-01

Similar Documents

Publication Publication Date Title
NZ748592A (en) Treatment for parkinson’s disease
ZA202202097B (en) Amino pyrimidine ssao inhibitors
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
PH12018502427A1 (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
MY196749A (en) Eif4a-inhibiting compounds and methods related thereto
MX384868B (es) Composiciones para tratar atrofia muscular espinal.
MY174284A (en) Compounds for treating spinal muscular atrophy
MX2017014584A (es) Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
AU2018253590A1 (en) Imidazopyridazine compounds
MY206763A (en) Piperidinyl-3-(aryloxy)propanamides and propanoates
NZ752587A (en) Lsd1 inhibitors and medical uses thereof
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
CO2019002517A2 (es) Inhibidores de dopamina–β–hidroxilasa
TN2018000372A1 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions.
MX2020001875A (es) Forma polimorfica de tg02.
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
MX380758B (es) Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo.
JOP20190163B1 (ar) منشط nrf2
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.